---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123279"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:41:42.844572+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q3 revenue $19.5M (+44% YoY); amends OrbiMed debt, removes $50M tranches

## Summary
- Commercial revenue $19.5M, up 44% YoY; gross margin 83.7% vs 84.5%.
- Net loss $16.2M ($0.62 loss per share) vs $8.7M loss in prior year quarter.
- Amended OrbiMed credit agreement: terminated two $50M tranches, removed Q4 2024 revenue covenant.
- Full-year 2024 revenue guidance reaffirmed at $68-70M (37-41% growth); Q4 guidance $22.3-24.3M.
- Expects RECELL GO mini FDA approval by Dec 31, 2024; Cohealyx launch Jan 2025.

## SEC filing metadata
- accession: 0000950170-24-123279
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017024123279/0000950170-24-123279-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017024123279/rcel-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123279
- JSON: https://secwatch.observer/filing/0000950170-24-123279.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123279.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.